Truist Securities Reiterates Buy on Verona Pharma, Maintains $32 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Joon Lee has reiterated a Buy rating on Verona Pharma (NASDAQ:VRNA) and maintained a $32 price target.
June 27, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Joon Lee reiterated a Buy rating on Verona Pharma and maintained a $32 price target.
The reiteration of a Buy rating and maintenance of a $32 price target by Truist Securities analyst Joon Lee indicates a positive outlook for Verona Pharma's stock. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100